Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | Highlights from SITC 2021 on immunotherapy in solid tumors

Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, describes the Phase Ib/II trial (NCT02501096) exploring lenvatinib plus pembrolizumab in patients with selected solid tumors, including advanced refractory endometrial cancer. Results demonstrated an impressive overall survival among a subgroup of patients with microsatellite instability (MSI)–high tumors and mismatch repair (MMR) deficiency. Additionally, the first-in-human Phase I EVICTION (NCT04243499) dose escalation trial evaluating the novel combination of ICT01 plus pembrolizumab in patients with advanced cancer is outlined. In this Phase I trial, although predominantly stable disease and stable responses were observed, there was a case of PD-1 refractory melanoma with intercranial metastasis that demonstrated complete regression. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.